Navigation Links

Cell Therapeutics Inc (Seattle WA) has agreed to pay the US $10.5 millon to resolve allegations of the company's alleged illegal marketing// of the anti-cancer prescription drug Trisenox, the US Justice Department announced earlier this month.

According to the government's complaint, CTI promoted the drug for various uses that were unapproved by the US Food & Drug Administration (FDA).

The alleged "off-label" uses caused doctors to prescribe Trisenox to treat various forms of cancer for which the drug was neither approved by the FDA, nor proven to be either safe or effective. The government's suit alleged that because of the company's actions, physicians who prescribed Trisenox off-label unwittingly submitted false claims for reimbursement to the Medicare program from 2001-05. In 2005, CTI sold Trisenox to another company, and the drug's new owner halted CTI's misleading off-label promotion campaign.

"Cell Therapeutics essentially subverted a regulatory system designed to assure that patients receive only those drugs that have been proven to be effective for their illness," said Peter D. Keisler, Asst Attorney General for the Justice Dept's Civil Div.

Under the rules in effect at the time of the conduct in question, the complaint asserts that Medicare paid only for anti-cancer drugs when prescribed for FDA-approved uses, or uses that were determined to be medically accepted as published in certain specific pharmacological texts known collectively as the compendia. The government alleges that CTI knew that Trisenox was FDA-approved for only one type of cancer and was not listed as a medically accepted treatment in the compendia for any other condition. Nevertheless, the complaint states and claims that CTI falsely marketed the drug to doctors by suggesting that Trisenox was FDA-approved and listed as medically accepted in the compendia for other types of cancers.

"Cell Therapeutics enriched itself at taxpaye r expense by aggressively marketing this drug to doctors for use in treating certain types of cancers, even though the company knew that the drug had no proven medical benefit in the treatment of those cancers and had not been approved by the FDA for those uses," said Jeffrey C. Sullivan, US Attorney for the W District of WA.

In addition, the government's complaint alleges CTI used illegal kickbacks to induce physicians to prescribe Trisenox. Under sham "consulting agreements," physicians were paid $500-$1,000 to attend dinners or conferences on the off-label uses of Trisenox. These meetings were held at expensive resorts and restaurants. Doctors who wrote large numbers of prescriptions for Trisenox for off-label uses were asked to speak at various events for additional financial bonuses.


Related medicine news :

1. Mystery Surrounding Use Of Abortion Pill Yet To Be Resolved
2. Kenya Resolves to Fight Tuberculosis
3. Dispute in Findings about Radiation exposure
4. Radiographers Pay Parity Disputes Still Unresolved
5. More Accurate "PROSTATE CANCER" Test can save Unnecessary Biopsies
Post Your Comments:

(Date:6/27/2016)... ... June 27, 2016 , ... ... health professionals, announced today its affiliation with Tennessee Counseling Association. This ... the network of the Tennessee Counseling Association, adding exclusive benefits and promotional offers. ...
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal ... personalized through a fitness app. The fitness app plans to fix the two major problems ... offer a one size fits all type program , They don’t eliminate all ...
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... and INDIANAPOLIS , June ... receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is any ... scholarship winners, announced today online at ... type 1 diabetes stand in the way of academic ... supported the Foundation,s scholarship program since 2012, and continues ...
Breaking Medicine Technology: